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Hepatitis Group; SMR, standardThere have been few reproducible studies of mortality in patients with autoimmune hepatitis
(AIH) and its variants. We calculated mortality in a large national cohort of patients with AIH,
with vs without cirrhosis, in the Netherlands.METHODS: We collected data from 449 patients with established AIH (77% female), from 6 academic and
10 non-academic hospitals in the Netherlands. We identified 29 patients with AIH and primary
biliary cholangitis and 35 patients with AIH and primary sclerosing cholangitis (AIH-PSC).
Mortality and liver transplantation data were assessed from August 1, 2006 through July 31,
2016. Standardized mortality ratios (SMR) were calculated using age-, sex-, and calendar year-
matched mortality for the general Dutch population.RESULTS: During the 10-year follow-up period, 60 patients (13%) died (mean age, 71 years; range,
33–94 years). Twenty-six causes of death were liver related (43%), whereas the others
could not be attributed to liver disease. Patients with AIH and cirrhosis had significantly
higher mortality than the general population (SMR, 1.9; 95% CI, 1.2–3.4), whereas patients
without cirrhosis did not (SMR, 1.2; 95% CI, 0.8–1.8). Patients with AIH-PSC had the
largest increase in mortality, compared to the general population (SMR, 4.7; 95% CI, 1.5–
14.6), of all groups analyzed. Mortality in patients with AIH and primary biliary cholangitis
was not greater than the general population. Four or more relapses per decade or not
achieving remission was associated with an increase in liver-related death or liver trans-
plantation. Nine patients underwent liver transplantation; 2 died from non-liver related
causes. Four of 9 patients on the waitlist for transplantation died before receiving a
donated liver.er: AIH, autoimmune hepatitis; AIH-PBC,
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April 2019 Mortality in Autoimmune Hepatitis Patients 941CONCLUSION: In an analysis of data from a large national cohort of patients with AIH, we found increased
mortality of patients with cirrhosis, but not of patients without cirrhosis, compared to the
general Dutch population. Survival was significantly reduced in patients with AIH and features
of concurrent PSC.Keywords: Long Term; Outcome; Autoimmune Liver Disease; Relapse; Remission.Autoimmune hepatitis (AIH) is a chronic immune-mediated inflammatory condition. Therapy is
aimed to prevent disease progression to fibrosis,
cirrhosis, and eventually liver failure and death. Since
the introduction of corticosteroid drugs and steroid
sparing thiopurine agents, prognosis has improved
dramatically.1,2 While some studies report that patients
with AIH have a good prognosis and normal survival,3–5
others contradict these findings.6,7 AIH may coexist with
primary biliary cholangitis (AIH-PBC) or primary scle-
rosing cholangitis (AIH-PSC) and recent data suggest
that particularly these patients have an impaired
outcome.8
We previously assessed the incidence and prevalence
of AIH in The Netherlands and generated a database of
patients derived from general and tertiary referral hos-
pitals.9 This cohort has been closely followed. Here, we
assessed the mortality and causes of death during 10
years in a clinical cohort of patients with established
with vs without cirrhosis and compared this with the
general Dutch population.Materials and Methods
Patient Population
Patients with a probable or definite diagnosis of AIH
according to the revised original score of the Interna-
tional Autoimmune Hepatitis Group (IAIHG)10 were
identified by searching the database of the Dutch Auto-
immune Hepatitis Study Group. The study protocol was
approved by the institutional review boards of all 6 ac-
ademic and 10 general hospitals in the Netherlands that
participated.
Patients who were alive at the start of the observation
period (August 1, 2006), did not have a history of liver
transplantation, and had follow-up data available in the
medical records were eligible for inclusion. In total, 506
records were reviewed and 449 patients were included.
Fifty-seven were excluded for the following reasons: 13
patients were not alive at start of follow-up; 7 patients
had undergone liver transplantation before August 1,
2006; and 37 patients did not have follow-up data. In
411 (92%) patients in the study-cohort a liver biopsy
was performed, in 38 patients liver biopsy report was
not performed or the report could not be retrieved.
The diagnosis of AIH was confirmed in all patients
using the revised IAIHG score. All patients had a revised,post-treatment IAIHG score of 12, confirming the
diagnosis of AIH.
Biochemical relapse was defined as an alanine
aminotransferase (ALT) >3 times upper limit of normal
or an increase of the immunoglobulin G level to >20g/L.1
Loss of complete biochemical remission was defined as
an increase in ALT above the upper limit of normal on 2
occasions with a time interval of at least 4 weeks.11 The
time to initial remission was defined as the time between
diagnosis and biochemical remission. Variant syndrome
AIH-PSC was defined as AIH with concurrent PSC based
on characteristic liver histology and cholangiographic
findings (magnetic resonance cholangiopancreatography
and/or endoscopic retrograde cholangiopancreatog-
raphy). The variant with concurrent PBC was defined as
AIH with an antimitochondrial antibody titer of >1:80 in
combination with compatible histology.9
Treatment details of immunosuppressive therapy
were assessed from the date of diagnosis to the end of
follow-up. The cumulative years of medication were
registered as the average dose in milligrams per day over
1-year intervals.Mortality and Liver Transplantation
Mortality and liver transplantation were assessed
during 10 years from August 1, 2006, until July 31, 2016
(end of study). Information on mortality and causes of
death were retrieved from medical records and/or by
contacting the attending physicians or general practi-
tioners. Liver transplantations were assessed by cross-
checking our cohort with data from the 3 liver trans-
plantation centers in the Netherlands. Follow-up ended
at the date of death or liver transplantation, or at the end
of the study. The cumulative person-years at risk was
4214 years, with a mean of 9.4 years/patient.Prognostic Factors
Baseline and follow-up data regarding the age at the
start of follow-up, cirrhosis, time to initial remission,
amount of relapses and loss of remission, immunoglob-
ulin G and ALT at diagnosis, variant syndromes, and
medication regimes were compared between patients
who survived and patients with a liver event (liver-
related death or transplantation) in a descriptive
manner. Cirrhosis was defined by the pathologist based
on liver histology.
What You Need to Know
Background
Autoimmune hepatitis (AIH) is a chronic immune-
mediated inflammatory liver disease. There are few
data and contradictory findings on mortality of pa-
tients with AIH or its variants.
Findings
Survival times of patients with AIH do not differ
significantly from those of the general Dutch popu-
lation unless patients also have cirrhosis or primary
sclerosing cholangitis.
Implications for patient care
Patients with AIH require close monitoring to pre-
vent cirrhosis. Survival times of patients with AIH are
shortened by the liver disease itself, rather than by
systemic effects of AIH or treatment-related serious
adverse events.
942 van den Brand et al Clinical Gastroenterology and Hepatology Vol. 17, No. 5Reference Population
The expected number of deaths in the AIH cohort was
calculated using age, gender and calendar year specific
mortality risks (2006–2016) retrieved from Statistics
Netherlands. For calculation of the expected death,
mortality rates of 1-year age groups in 1-year periods
(1  1 format) were used, hence, ageing was taken into
account. Standardized mortality ratios (SMRs), defined as
the observed deaths / expected deaths, were used to
compare the AIH cohort to the general Dutch population.
Liver-related deaths in our cohort were compared simi-
larly with the general population using expected number
of deaths for the International Classification of
Diseases–Tenth Revision codes K72-K76 and C22. These
codes include deaths due to hepatic failure, cirrhosis,
chronic hepatitis, other (inflammatory) liver diseases,
and malignant neoplasm of liver and intrahepatic bile
ducts, and do not include deaths due to alcoholic, drug-
induced, viral, parasitic, and other infectious liver
diseases.
Statistical Analysis
Normally distributed variables were described as
mean  SD, and non-normally distributed variables were
described as median with range or interquartile range if
stated. Categorical data was described as number and
percentage of total. Overall survival curves were ob-
tained via Kaplan-Meier estimate. For differences in
survival between 2 or more groups the log-rank test was
used. Patients who received a liver transplantation were
censored for analysis at the date of transplantation. The
composite endpoint of liver-related death and trans-
plantation was used to compare disease related events in
AIH and its variants using Cox analysis. Ordinal and
continuous variables were compared between 2 groups
with the Mann Whitney test (non-normal) or 2-sided
samples t test (normal). For bimodal outcome vari-
ables, 2-sided Fisher’s exact was used. In case continuous
variables of 3 groups were compared, analysis of vari-
ance (normal distribution) or the Kruskal-Wallis (non-
normal) test was used. Post hoc analyses for correction
of multiple testing were performed with the Bonferroni
in case of analysis of variance and Dunn-Bonferroni in
case of the Kruskal-Wallis test. The significance level (a)
was set at .05. Statistical analysis were performed with
IBM SPSS 22.0 (IBM Corp, Armonk, NY). Kaplan-Meier
curves were computed with GraphPad Prism 7.02
(GraphPad Software, La Jolla, CA).
Results
Diagnostic characteristics and outcome parameters
are summarized in Table 1 and included 385 patients
with AIH, 29 with AIH-PBC, and 35 with AIH-PSC. The
cumulative number of patient-years from diagnosis tothe end of follow-up was 7217 years. All patients had a
revised AIH score of 12 (post-treatment).10 Viral hep-
atitis B and C was excluded in 446, unknown in 1, and
positive in 2 patients before AIH was diagnosed. Previ-
ously, the prevalence of hepatitis E was tested in a
representative group of 136 patients with AIH in our
cohort. No cases of acute hepatitis E virus infection were
identified, whereas 29 patients had been exposed.12 Anti-
nuclear antibodies and anti–smooth muscle antibodies
were positive in 61% of tested patients (n ¼ 395) and in
63% (n ¼ 379), respectively. In total, 86% were positive
for anti-nuclear antibodies or anti–smooth muscle anti-
bodies, in 37 (8%) patients results were not available.
Anti-liver/kidney microsomal antibody type 1, charac-
teristic for AIH type 2, was positive in 17 (6%) of 285
tested patients. In 61 (14%) patients AMA or histology
results were not available. Treatment details of the initial
and last year of treatment are shown in Supplementary
Table 1.
Relapse
A total of 200 (45%) patients experienced 1 or more
relapses. Of these patients, 25 (13%) were weaned from
therapy when this first relapse occurred, and 150 (87%)
patients relapsed while on immunosuppressive therapy.
Mortality
During the 10-year follow-up, 55 (14%) AIH patients
died at a mean age of 73 (range, 33–94) years, a median
time of 142 (range, 12–471) months after diagnosis. In
addition, 2 (7%) patients with AIH-PBC died at the 44
and 54 years of age and 3 (9%) AIH-PSC patients died at
the 53, 56, and 57 years of age; all more than 10 years
after diagnosis.
Table 1. Characteristics at Diagnosis and Outcome Parameters
AIH AIH-PBC AIH-PSC P Value
Characteristics at diagnosis
Patients 385 (86) 29 (6) 35 (8)
Female 300 (78) 27 (93) 21 (60) .006a
Age, y 46 (2–88) 46 (16–70) 30 (12–54) <.001b
MELD score 10 (0–22) 8 (1–22) 7 (2–17) .327
IgG, g/L 29  13 24  13 23  9 .110
ALT, U/L 518 (214–1052) 274 (85–623) 273 (136–701) .007c
Cirrhosis 52 (18) 4 (14) 1 (3) .133
ANA and/or SMA positive 325 (91) 19 (70) 29 (94)
ANA positive 260 (76) 13 (52) 21 (70)
SMA positive 216 (66) 13 (54) 19 (63)
10-y follow-up
Time since diagnosis, y 6 (0–34) 5 (0–8) 5 (0–29)
Cirrhosis development 20 (6) 0 3 (9)
Liver transplantation 4 (1) 2 (7) 3 (9)
Deaths 55 (14) 2 (7) 3 (9)
Causes of death
Hepatobiliary diseases 22 (40.0) 1 (50.0) 3 (100.0)
Circulatory system diseases 12 (21.8) 1 (50.0)
Respiratory system diseases 2 (3.6)
Malignant diseases 12 (21.8)
Other causes of death 5 (9.1)
Unknown 2 (3.6)
NOTE. Values are n (%), median (interquartile range), or mean  SD.
AIH, autoimmune hepatitis; AIH-PBC, autoimmune hepatitis with concurrent primary biliary cholangitis; AIH-PSC, autoimmune hepatitis with concurrent primary
sclerosing cholangitis; ALT, alanine aminotransferase; ANA, anti-nuclear antibody; IgG, immunoglobulin G; MELD, Model for End-Stage Liver Disease; SMA,
smooth muscle antibody.
aPost hoc analysis showed significant differences between AIH and AIH-PSC (P ¼ .044), AIH-PSC and AIH-PBC (P ¼ .005).
bPost hoc analysis showed significant differences between AIH and AIH-PSC (P < .0001) and between AIH-PBC and AIH-PSC (P < .001).
cPost hoc analysis showed a significant (P ¼ .029) difference between AIH and AIH-PBC.
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in AIH patients with cirrhosis at any time in the disease
course and not in AIH patients without cirrhosis
(Table 2). To prevent bias due to an overestimation of
IAIHG score in the included population, we performed
additional stringent analyses after the exclusion of the 61
patients who did not have histology or AMA results, as
biliary changes and a positive AMA may deduct points onTable 2. SMR
Observed Expected SMR 95% CI
Liver disease–related death 26 0.5 55.2 37.6–81.7
Non–liver disease–related
death
34 40.6 0.8 0.6–1.2
Overall mortality
AIH 55 38.8 1.4 1.1–1.8
Noncirrhotic 26 21.5 1.2 0.8–1.8
Cirrhotica 14 7.3 1.9 1.2–3.4
Age 50 yb 12 5.6 2.1 1.3–4.0
Age >50 yb 43 33.2 1.3 0.9–1.8
AIH-PBC 2 1.6 1.2 0.3–4.9
AIH-PSC 3 0.6 4.7 1.5–14.6
AIH, autoimmune hepatitis; AIH-PBC, autoimmune hepatitis with concurrent
primary biliary cholangitis; AIH-PSC, autoimmune hepatitis with concurrent
primary sclerosing cholangitis; CI, confidence interval; SMR, standardized
mortality ratio.
aCirrhosis at any time from diagnosis to the end of follow-up.
bAge at the start of the 10-year follow-up.the revised AIH criteria. These analyses were similar to
the overall included population (Supplementary Table 2).
Kaplan Meier estimates of patients with AIH are
shown in Figure 1. Comparison with age and gender-
matched population controls shows an increased
overall mortality in patients with AIH. Overall survival of
AIH-PBC patients was similar (P ¼ .71) and survival of
AIH-PSC patients was decreased compared with theFigure 1.Overall survival was decreased (P ¼ .022) in pa-
tients with autoimmune hepatitis (AIH) compared with the
age- and gender-matched Dutch population.








Patients 414 (92) 35 (8)
Female, % 78 71 .399
Cirrhosis anytime 68 (16) 11 (31) .013
Relapse þ LOR 2 (0–4) 2 (0–4) .876
Remission achieved 375 (91) 29 (83) .126
Time to remission, mo 4 (0–167) 3 (1–35) .825
Second- or third-line
therapy
42 (10) 13 (37) <.001
First-line treatment 387 (95) 34 (97) .643
Prednisone and
azathioprine
292 (72) 26 (77) -
Prednisone monotherapy 62 (15) 6 (18) -
Azathioprine monotherapy 33 (8) 1 (3) -
At the time of diagnosis
Age, y 43 (2–88) 47 (10–81) .183
MELD score 10 (0–32) 11 (5–22) .199
Creatinine, mmol/L 73 (40–158) 66 (47–98) .195
Bilirubin, mmol/L 38 (4–719) 48 (9–353) .368
INR 1.1 (0.8–4.7) 1.3 (1.0–4.1) .006
Albumin, g/L 38 (17–54) 35 (26–44) .013
Platelets ( 109/L) 210 (61–634) 142 (63–232) <.001
ALT, U/L 484 (13–4693) 228 (36–3080) .259
IgG, g/L 26 (7–91) 23 (9–51) .860
NOTE: Values are n (%) or median (range), unless otherwise indicated.
ALT, alanine aminotransferase; IgG, immunoglobulin G; INR, international
normalized ratio; LOR, loss of remission; MELD, Model for End-Stage Liver
Disease.
Table 4. Survival of Liver-Related Death and Liver
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Figure 1).
Survival of the composite endpoint of liver-related
mortality or liver transplantation was impaired in AIH
patients with cirrhosis compared patients without
cirrhosis (Figure 2). Patients who reached this composite
endpoint had significantly more cirrhosis, higher inter-
national normalized ratio and lower platelet and albumin
levels compared with patients who survived (Table 3).
In uni- and multivariate Cox analysis age, cirrhosis,
AIH-PSC, 4 or more relapses per decade, or not achieving
remission were predictors for the composite liver-
related endpoint, whereas AIH-PBC, a pediatric disease
onset, gender, or <4 relapses per decade were not
(Table 4). Additional analysis of liver-related deaths in
AIH patients without censoring liver transplantations
shows that patients who died of liver-related events had
histological proven cirrhosis more often compared
with patients who survived (41% vs 19%; P ¼ .01). In
this Cox regression analysis, histological proven cirrhosis
(P < .001), corrected for age at baseline, was a predicting
factor (P ¼ .001) for liver-related death.
Supplementary Figure 2 shows survival of the com-
posite liver-related endpoint for patients with AIH, AIH-
PBC, and AIH-PSC.
Twenty-three patients developed cirrhosis during
therapy, of whom 15 had fibrosis (stage 1–3) at diag-
nosis. In all cases, cirrhosis was histologically confirmed
before August 1, 2006. Both patients who had cirrhosis
at diagnosis (hazard ratio, 2.5; 95% confidence interval,
1.0–6.2; P ¼ .05) and patients who developed cirrhosis
after diagnosis (hazard ratio, 4.6; 95% confidence in-
terval, 1.5–14.0; P < .01) had an increased risk of liver-
related death or liver transplantation, when compared
with patients without cirrhosis.
The cause of death was established in 58 patients
(Table 1). Hepatobiliary disease accounted for 26 deaths,Figure 2. Survival of the composite endpoint of liver-related
death or liver transplantation was significantly decreased in
patients with autoimmune hepatitis and cirrhosis compared
with autoimmune hepatitis patients without cirrhosis (P ¼
.030).resulting in a marked increase of liver-related mortality
in AIH (SMR, 50.0; 95% confidence interval, 33.0–76.0),
AIH-PBC (SMR, 48.3; 95% confidence interval,
6.8–343.2), and AIH-PSC (SMR, 278.3; 95% confidenceTransplantation
Univariate Multivariate
HR (95% CI) P Value HR (95% CI) P Value
Age 1.0 (1.0–1.0)a .02a 1.1 (1.0–1.1)a <.01a
Gender 0.7 (0.3–1.5) .4
Cirrhosis 2.1 (1.0–4.3)a .05a 2.2 (1.1–4.6)a .04a
AIH-PBC 1.5 (0.5–5.0) .5
AIH-PSC 2.5 (1.0–6.1) .04a 4.8 (1.7–13.7)a <.01a
Pediatric onset 0.4 (0.1–1.4) .4
Relapses per
decade
0b - - - -
0.1–1.99 1.2 (0.5–2.9) .7
2.0–3.99 2.2 (0.8–6.3) .2
4.0 5.4 (1.4–20.2)a .01a 5.7 (1.4–23.6)a .02a
Remission not
achieved
2.9 (1.0–8.2)a .05a 3.9 (1.2–12.7)a .02a
AIH, autoimmune hepatitis; AIH-PBC, autoimmune hepatitis with concurrent
primary biliary cholangitis; AIH-PSC, autoimmune hepatitis with concurrent
primary sclerosing cholangitis; CI, confidence interval; HR, hazard ratio.
aReference category.
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population. Patients who died due to hepatobiliary dis-
ease encountered multiple (n ¼ 47) complications
contributing to death (Supplementary Table 3). The 3
patients who died due to hepatocellular carcinoma had
cirrhosis. The estimated incidence of mortality due to
HCC in patients with cirrhosis at diagnosis in our study
was 3.6 per 1000 patient-years at risk. In 2 patients, the
cause of death could not be unraveled. Survival of pa-
tients who deceased due to non–liver-related causes was
not different from the general population, indicating that
excess mortality is driven by the underlying liver disease
(Table 2).
Death likely related to immunosuppressive therapy
occurred in one 44-year-old patient who died due to a
pulmonary aspergillus infection while being treated with
budesonide, ciclosporin, and mycophenolate mofetil.
Mortality due to extrahepatic malignancies included
melanoma (n ¼ 1), lung cancer (n ¼ 2), prostate cancer
(n ¼ 1), colorectal cancer (n ¼ 3), vulvar cancer (n ¼ 1),
urothelial cancer (n ¼ 1), ovarian cancer (n ¼ 1), and 2
metastatic malignancies with unknown primary tumors.
Patients who died due to hepatobiliary causes
deceased at a significantly younger age than did those
who died of other causes (median age 68 vs 80 years,
P ¼ .013). Subgroup analysis for age at start of follow-up
revealed that patients 50 years of age or younger had a
higher SMR than patients older than 50 years of age,
compared with the all-cause mortality of the general
population (Table 2). This could be explained by the low
number of deaths in the general population 50 years of
age or younger.
Survival rates of patients who were managed in aca-
demic hospitals and nonacademic hospitals were com-
parable (87% vs 84%; P ¼ .27).
Liver Transplantation
During the 10-year follow-up, 9 (2%) patients were
transplanted at a median age of 48 (range, 27–67) years,
of whom 4 were AIH patients (1%), 2 were AIH-PBC
patients (7%) and 3 were AIH-PSC patients (9%).
Seven transplanted patients were alive at the end of
follow-up, 2 died of extrahepatic malignancies (lung
cancer and melanoma) and were censored for mortality
analysis at the date of transplantation. In addition, 4 AIH,
2 AIH-PBC, and 3 AIH-PSC patients were positively
screened for, but did not receive, a liver transplantation.
Two AIH, 1 AIH-PBC, and 1 AIH-PSC patient died of liver-
related disease while waiting for a donor liver.
Discussion
Published data on mortality rates in AIH patients and
its variants are scarce and contradictory. In some small
and mostly single center studies the observed mortality
rates of AIH patients was comparable to the generalpopulation.3–5 Other larger studies showed an increased
mortality in AIH patients SMR.3–6,13–18 As far as we
know the current study comprises the largest cohort of
patients with established AIH and a follow-up of >10
years. Patients were recruited from general hospitals,
tertiary referral centers, and transplantation hospitals
and thus reflects a realistic representation of “real
world” AIH. The findings of our study are reassuring.
Patients without cirrhosis have a normal life expectancy.
Only patients with cirrhosis and particularly AIH-PSC
patients have an impaired survival, which can be
entirely attributed to liver-related complications. No
excess mortality was seen in deaths unrelated to the
underlying liver disease which is in line with findings of
Hoeroldt et al,6 suggesting that the liver disease and no
other factors, including therapy, are responsible for the
excess mortality.
We found that liver disease was responsible for
approximately one third of the deaths in AIH patients,
consistent with 39%–55% of deaths accounted to liver
disease in other studies.7,15 These studies did not report
the number of patients with variant syndromes, which
generally constitutes a proportion of 10%–15% of AIH
patients.19 In this study, we addressed differences in
outcomes among AIH, AIH-PBC, and AIH-PSC. We found
that increased overall mortality rate was most profound
in the relatively young group of AIH-PSC patients, which
was entirely attributable to the underlying liver disease.
No excess mortality was seen for AIH-PBC patients.
Although the latter finding may be explained by the small
number of patients in this group, it is consistent with
other reports in the literature.20 AIH-PBC was defined as
AIH with features of PBC and compatible histology,
which is less stringent than the Paris criteria; however,
we were not able to perform a centralized review of bi-
opsies. The incidence of mortality due to HCC in patients
with cirrhosis at diagnosis was markedly lower in our
study than the incidence of HCC in found by Tansel
et al.21 This may in part be explained by the difference in
study design. Furthermore, we cannot exclude that the
HCC incidence is underestimated because of missing
cases, as cross-referencing with the Dutch cancer registry
was not possible.
In our cohort of relatively young patients, 8% of the
patients reached the composite liver disease endpoint of
liver-related death or liver transplantation over a 10-
year period. Cirrhosis, age, AIH-PSC, more than 4 re-
lapses per decade, and not achieving remission were
prognostic for this composite liver-related outcome in
uni- and multivariate Cox analysis, which is in line with
other studies.6,22 Prior studies have shown that pediatric
onset patients have a more aggressive disease course, yet
we did not observe a correlation between a pediatric
onset and liver-related endpoints, which is likely due to
the relatively low number of pediatric onset patients in
our cohort.23,24
Patients who reached the composite liver-related
outcome had lower platelet counts, lower albumin
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cirrhosis more frequently, compared with patients who
survived. The differences in laboratory values are likely a
result of cirrhosis; however, this could not be confirmed
in our study in an independent multivariate analysis,
because of incomplete data capture on the laboratory
parameters. In support of this figure, cirrhosis was
identified using albumin, international normalized ratio,
and the platelet count in a meta-analysis of patients with
liver disease.25
Survival of patients with cirrhosis in our cohort was,
again, reduced when liver-related deaths without liver
transplantations were analyzed, furthermore confirming
the prognostic value of cirrhosis. Hence, even when
transplantation is successful, cirrhosis is still prognostic
for liver-related death. Both patients with cirrhosis at
diagnosis and patients who developed cirrhosis during
the disease course had an impaired survival of the
composite liver-related endpoint, compared with pa-
tients without cirrhosis. Not surprisingly, second- or
third-line therapy were more frequently required during
the disease course of patients who eventually reached
the composite liver-related endpoint. Malignancies have
been reported in relation to long-term immunosuppres-
sive therapy.26 In our cohort no excess of non–liver-
related mortality including mortality due to malignancies
was noticed, although 1 patient died of causes related to
immunosuppressive therapy. The decreased survival was
driven by the underlying liver disease and not by sys-
temic effects of AIH or treatment related serious adverse
events. The number of patients subjected to liver trans-
plantation was low (2%) in our cohort compared with
reported numbers of 10%27 and 5%15 reported in 2006
and 2010, respectively. In our cohort another 9 (2%)
patients were listed for liver transplantation, of whom 4
died without being transplanted. Patients with variant
syndromes were more likely to be placed on the trans-
plantation list than AIH patients.
The strengths of this study are defined by the largest
number of included patients with established AIH in both
transplant, nontransplant and general referral hospitals,
and the certainty that no patients who reached an
endpoint were missed. In addition, the design of this
cohort study, following onward those AIH patients who
were alive in 2006, allowed for a SMR assessment
compared with the general Dutch population. However,
those patients who had reached an endpoint before
baseline were excluded due to this study design. This fact
and the expected boundaries of a retrospective study,
such as missing data, precluding large scale multivariate
regression analysis, are limitations that should be noted.
We aimed to address these issues by performing a
stringent analysis approach in those patients with
missing data in histology and AMA status.
In conclusion, patients with AIH without cirrhosis
have a similar survival rate as the general population.
Patients with AIH and cirrhosis and patients with an AIH-
PSC variant syndrome have a significant increased riskof death and liver transplantation. This impaired
survival rate can entirely be attributed to liver-related
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Supplementary Figure 1. Kaplan-Meier estimates of overall survival. (A) Survival of patients with autoimmune hepatitis with
primary sclerosing cholangitis (AIH-PSC) was decreased compared with the age- and gender-matched population (P ¼ .009)
(B) Cumulative survival of AIH with concurrent primary biliary cholangitis (AIH-PBC) did not differ from the age- and gender-
matched population (0.714).
Supplementary Figure 2. Survival functions of patients with
autoimmune hepatitis (AIH), AIH with concurrent primary
biliary cholangitis (AIH-PBC) and AIH with primary sclerosing
cholangitis (AIH-PSC) for the composite endpoint of liver-
related death or liver transplantation (P ¼ .081).
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Supplementary Table 1. Treatment Details of in the First and Last Year of Treatment
Initial Year of Treatment Last Year of Treatment
Patients Dose (mg/d) Patients Dose (mg/d)
Prednisone 304 (86) 10 (1–60) 164 (40) 5 (1–40)
Budesonide 4 (1.1) 8 (3–9) 45 (11) 6 (1–9)
Azathioprine 233 (66) 50 (4–200) 256 (62) 75 (13–200)
Second line
Mycophenolate mofetil 4 (1.1) 1500 (250–2000) 23 (5.5) 1000 (500–2000)
Ciclosporin 1 (0.3) 150 6 (1.4) 125 (50–200)
Tacrolimus — — 5 (1.2) 5 (1–7)
Mercaptopurine — — 7 (1.7) 50 (25–75)
Thioguanine 1 (0.3) 16 3 (0.7) 21 (3–50)
NOTE. Values are n (%) or median (interquartile range). The mean time interval between initial and last year of treatment was 16  7 years.
Supplementary Table 2. Stringent SMR Analysis
Death
SMR 95% CIObserved Expected
Liver disease–related death 23 0.4 56.7 37.7–85.3
Non–liver disease–related
death
32 36 0.9 0.6–1.3
Overall mortality
AIH 50 33.4 1.5 1.1–2.0
Noncirrhotic 24 20.5 1.2 0.8–1.7
Cirrhotica 14 7.2 1.9 1.2–3.3
Age 50b 13 5.6 2.3 1.3–4.0
Age >50 yb 37 27.8 1.3 1.0–1.8
AIH-PBC 2 1.4 1.4 0.4–5.6
AIH-PSC 3 0.6 5.0 1.6–15.6
NOTE. AIH, autoimmune hepatitis; AIH-PBC, autoimmune hepatitis with con-
current primary biliary cholangitis; AIH-PSC, autoimmune hepatitis with con-
current primary sclerosing cholangitis; CI, confidence interval; SMR,
standardized mortality ratio.
aCirrhosis at any time from diagnosis to the end of follow-up.
bAge at the start of the 10-year follow-up.
Supplementary Table 3. Complications Contributing to








Decompensated cirrhosis or liver
insufficiency
17 1 2
Gastrointestinal hemorrhage 6 1
Hepatocellular carcinoma 2 1
Cholangiocarcinoma 1








NOTE. Some patients encountered more than 1 complication.
AIH, autoimmune hepatitis; AIH-PBC, autoimmune hepatitis with concurrent
primary biliary cholangitis; AIH-PSC, autoimmune hepatitis with concurrent
primary sclerosing cholangitis.
aOne patient died due to Aspergillus pneumoniae and another patient had
severe dyspnea subsequent to liver failure.
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